VelaVigo was founded by Dr. Jing Li, a renowned biopharma executive, in October 2021. We leverage discovery as an innovative engine with an emphasis on novel technologies, including bispecific/multi-specific antibodies, ADC, and new modalities. We are committed to building full capabilities covering the entire value chain of drug discovery and development, including novel discovery technology platform, translational medicine, CMC, clinical development and commercialization. VelaVigo is building its global R&D headquarter in Shanghai, and will set up R&D footprint globally. VelaVigo combines internal discovery/development and win-win partnership to drive its portfolio. We strive to the development of innovative, affordable biological drugs to address unmet clinical needs for global patients.